A clinical and ultrastructural study of osteogenesis imperfecta after flavonoid (Catergen) therapy.
A trial of the flavonoid Catergen (Zyma) has been undertaken in 11 adults with osteogenesis imperfecta (Ol). The only significant clinical or metabolic side-effects were severe headaches, which necessitated the withdrawal of 3 patients from the trial. Patient compliance in terms of palatability of Catergen was good, and 3 of the 8 patients who completed the trial experienced subjective improvement. After 6 months' treatment with Catergen, the abnormally narrow collagen fibrils found in the osteoid region in a pretreatment bone biopsy specimen from a middle-aged man with the common type 1 (autosomal dominant) form of Ol showed a significant reversion to normal diameters. Post-treatment specimens from his 2 affected sons, who exhibited the same defect, showed a similar but less marked response.
D000328:Adult; D001578:Benzopyrans / Q000627:therapeutic use*; D001842:Bone and Bones / Q000648:ultrastructure; D002392:Catechin / Q000627:therapeutic use*; D003094:Collagen / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010013:Osteogenesis Imperfecta / Q000188:drug therapy / Q000473:pathology*; D013997:Time Factors
D001578:Benzopyrans; D002392:Catechin; D003094:Collagen